Using Trispecific T-Cell Engagers Alongside Checkpoint Inhibition to Enhance the Therapeutic Applications of TCEs
Time: 3:15 pm
day: Day 2
Details:
- Combining trispecific T-cell engagers with checkpoint inhibition to simultaneously target tumor cells, activate T-cells, and block immune suppressive pathways, enhancing antitumor immunity
- Optimizing trispecific T-cell engager design to improve tumor specificity, T-cell recruitment, and immune checkpoint blockade for synergistic therapeutic effects
- Exploring the clinical potential of trispecific engagers with checkpoint inhibitors in solid and hematologic tumors to improve response rates and reduce immune evasion
